Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement

On August 18, 2025, Bioxcel Therapeutics' stock surged by 18.8% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Bioxcel Therapeutics has recently made headlines with the announcement of a phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia. This trial is part of the company's ongoing efforts to develop innovative treatments for mental health conditions, which has been a key driver of investor interest.

The upcoming release of SERENITY At-Home trial data this month is another significant event that has contributed to the positive sentiment surrounding Bioxcel Therapeutics. The data is expected to provide further insights into the efficacy and safety of the company's treatments, potentially leading to regulatory approvals and expanded market opportunities.